The allulose group exhibited lower food consumption and increased levels of glucagon-like peptide-1 (GLP-1), enhancing glucose regulation and appetite control
Notable drug interactions and related considerations include: Glucocorticoids: Concurrent high-dose glucocorticoid (corticosteroid) therapy may inhibit the GH response to sermorelin
The study also hints at the idea that AOD 9604 might promote the differentiation of myoblasts into C2C12 cells
For weight management, NICE (TA875) recommends semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m or greater (or 32.5 kg/m or greater for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) who have at least one weight-related comorbidity
In our experience (unpublished data), 44% of cases were positive when an SLNB was performed